N@N

Carter Gould Upgraded (ABBV) to Buy and Increased Target to $170 on, Oct 30th, 2023

^{Published on 2024-10-28 07:10:16 - WOPRAI, Carter Gould}
 

Carter Gould of Barclays, Upgraded "AbbVie Inc." (ABBV) to Buy and Increased Target from $160 to $170 on, Oct 30th, 2023.

Carter has made no other calls on ABBV in the last 4 months.

There are 4 other peers that have a rating on ABBV. Out of the 4 peers that are also analyzing ABBV, 1 agrees with Carter's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Tim Lugo of "William Blair" Initiated at Hold on, Tuesday, July 25th, 2023

These are the ratings of the 3 analyists that currently disagree with Carter

---

• Gary Nachman of "Raymond James" Initiated at Buy and Held Target at $177 on, Friday, September 29th, 2023
• Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $170 on, Friday, July 28th, 2023
• Rajesh Kumar of "HSBC" Initiated at Strong Buy and Held Target at $167 on, Friday, July 14th, 2023

Contributing Sources

---